Klin Farmakol Farm. 2015;29(1):30-34

Insulin treatment options in 2015

Denisa Janíčková Žďárská, Pavlína Piťhová, Milan Kvapil

Interní klinika FN v Motole a 2. LF UK, Praha

The clinical practice has requiredthat novel typesof basal insulin analogues be developed. They are characterised bya lower intraindividual

variabilityof the effect, which meansbetter predictability of the effect and reduction in the riskof nocturnal hypoglycaemia, in particular.

This group includes insulin degludec, insulin glarginein aconcentrationof 300 IU, and pegylated insulin lispro, which exhibitshigher

affinityto the effect directly in the hepatic cell. The three novel typesof basal analogueswill all improve the safetyof treatmentin both

type 1 and type 2 diabetes.

Premixed analogues have also retained their place in the treatment, with their advantage beingconcurrentfasting as well as postprandial

glycaemia intervention. They are particularly intendedfor patients witha stableeverydaylife.

Keywords: basal analogue, premixed insulins, insulin degludec, insulin glargine U300, pegylated insulin lispro

Published: March 1, 2015  Show citation